Overview | November 26, 2025
FFPE Multi-Omics for Clinical Oncology
Get the Resource
Download NowClinical oncology programs require robust biomarkers for patient stratification, target engagement, and PK/PD data to guide enrollment, dosing, and patient response. FFPE trial samples are among the most accessible to enable this work, but because of challenges with formalin-induced cross-linking, FFPE tissue analysis has been traditionally limited to low-plex immunohistochemistry (IHC) or genomic sequencing, resulting in:
- Limited protein-level measure of target expression and tissue PK/PD modulation
- Slow identification of target engagement and patient responders
The result? Slower trials, non-optimized dosing, and missed responder subgroups.
Now, there's a new way to unlock actionable drug effect insights in FFPE tissue for smarter trials.
Sapient’s next-generation mass spectrometry-based FFPE Proteomics method delivers deep, quantitative proteomic data via the direct measure of >10,000 proteins in FFPE tissue. Targeted, quantitative assays can be optimized to evaluate key protein targets within clinical FFPE samples with exceptional reproducibility (inter-section CV < 8%).
Through deep, quantitative profiling, Sapient’s FFPE proteomics enables early detection of pathway modulation and target engagement to improve patient stratification and guide dose adjustments in early clinical phases.
Download the data sheet to see how our proteomics-based workflows for FFPE tissue analysis enable rapid re-analysis of archived trial biopsies to identify biomarkers, responder groups, and drug mechanism of action. Optimized for clinical programs with hundreds to thousands of FFPE samples, we can deliver results with rapid turnaround to support clinical biomarker confirmation and confident trial decision-making.
In fact, Sapient’s DynamIQ™ virtual biobank offers streamlined access to thousands of annotated FFPE tumors and tissues, enabling clinical teams to perform retrospective validation without new collections, accelerating biomarker qualification.
You’ll also see how Sapient’s FFPE Multi-Omics platform additionally integrates DNA sequencing, single-cell sequencing, and spatial profiling to map tumor biology from mutation to pathway activation to spatial localization – providing comprehensive molecular views of tumor pathology, drug effect, and patient response.